Citadel Advisors
LYEL icon

Citadel Advisors’s Lyell Immunopharma LYEL Stock Holding History

Citadel Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$241K Buy
+12,000
New +$281K ﹤0.01% 10993
2025
Q2 		– Sell
-145
Closed -$1.56K – 14000
2025
Q1 		$1.56K Sell
145
-240
-62% -$2.94K ﹤0.01% 14120
2024
Q4 		$4.93K Sell
385
-520
-57% -$10.3K ﹤0.01% 13891
2024
Q3 		$25K Buy
905
+775
+596% +$22.8K ﹤0.01% 12601
2024
Q2 		$3.77K Buy
+130
New +$6.19K ﹤0.01% 13549
2024
Q1 		– Sell
-65
Closed -$2.52K – 15117
2023
Q4 		$2.52K Sell
65
-445
-87% -$16K ﹤0.01% 13687
2023
Q3 		$15K Buy
510
+495
+3,300% +$23.5K ﹤0.01% 12844
2023
Q2 		$954 Sell
15
-35
-70% -$1.94K ﹤0.01% 14013
2023
Q1 		$2.36K Sell
50
-85
-63% -$4.54K ﹤0.01% 14161
2022
Q4 		$9.37K Buy
+135
New +$13.4K ﹤0.01% 13688

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Citadel Advisors's LYEL Position: Q1 2026 in Review

Citadel Advisors increased its Lyell Immunopharma (LYEL) stake by 17% in Q1 2026, buying an estimated $1.33M and bringing the position to 381,462 shares worth $7.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

Citadel Advisors first reported a position in LYEL in Q2 2021 and has held it in 18 quarters since. The position peaked at $9.99M in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Citadel Advisors held 381,462 shares of Lyell Immunopharma worth $7.65M as of Q1 2026.
  • Citadel Advisors bought 56,761 Lyell Immunopharma shares in Q1 2026, an estimated $1.33M.
  • Lyell Immunopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3653 holding.
  • Citadel Advisors first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Lyell Immunopharma position peaked at $9.99M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.